The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial

Abstract Background Neoadjuvant chemoimmunotherapy does not benefit all non-small cell lung cancer (NSCLC) patients, and reliable biomarkers are urgently needed. We conducted this prospective phase II trial of neoadjuvant chemoimmunotherapy to explore the role of cell-free DNA (cfDNA) features in pa...

Повний опис

Бібліографічні деталі

Автори:	Bing Liu, Ye Tao, Minglei Zhuo, Li-Di Xu, Xueyan Cheng, Wei Tao, Zhangdong Xie, Chao Lv, Yuzhao Wang, Shaolei Li, Shanyuan Zhang, Miao Huang, Yaqi Wang, Xiang Li, Yuge Zhu, Xinrui Cui, Xuantong Zhou, Bateer Han, Enli Zhang, Yu S. Huang, Weizhi Chen, Jia Wang, Shi Yan, Nan Wu
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2025-11-01
Серія:	BMC Medicine
Предмети:	Plasma cell-free DNA Methylation Pathological response Non-small cell lung cancer
Онлайн доступ:	https://doi.org/10.1186/s12916-025-04419-x
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!